Search

List Grid

331-340 of 1,789 results

  • Medicare and People with HIV

    Issue Brief

    This data note provides an overview of the role of the Medicare program for people with and at risk for HIV.

  • 10 Things About Long-Term Services and Supports (LTSS)

    Issue Brief

    Medicaid paid for more than half of the $415 billion that the US spent on long-term services and supports in 2022, most of which went to home and community-based services as well as to care in nursing homes and other institutional settings.

  • Standardized Plans in the Health Care Marketplace: Changing Requirements

    Issue Brief

    This brief examines the evolving requirements for insurers on HealthCare.gov to offer standardized plans that follow set cost sharing rules for covered benefits in addition to other plans they might offer. It also reviews how some state-run marketplaces have used standardized plans to limit cost sharing for insulin, mental health care, and other services.

  • Medicaid 101

    Feature

    This Health Policy 101 chapter explores Medicaid, the primary U.S. program providing comprehensive coverage of health care and long-term services and supports to about 80 million low-income people. Originating in 1965 and expanding with the Affordable Care Act, the chapter reviews Medicaid's evolution, including 2025 changes, and its joint federal and state financing and administration. It discusses how state-level flexibility in managing Medicaid leads to variation in coverage, spending, health care delivery, and access across…

  • What is the Potential Impact of New Drugs for Obesity and Alzheimer’s Disease on Medicare Costs, Coverage and Beneficiaries? 

    News Release

    Two new KFF analyses examine the potential impact of Medicare coverage of new prescription drugs for obesity and Alzheimer’s disease on program spending and beneficiary out-of-pocket costs, as well as the role that the Inflation Reduction Act could play in mitigating these effects. Manufacturers of both types of drugs are lobbying for broad Medicare coverage of them, though they face different challenges. The availability of effective weight-loss drugs, including Novo Nordisk’s Ozempic and Wegovy (semaglutide)…

  • The Semi-Sad Prospects for Controlling Employer Health Care Costs

    From Drew Altman

    In a commentary on KFF’s 27th employer health benefits survey, President and CEO Dr. Drew Altman discusses the obstacles employers face trying to control their health care costs, and the reasons why they’ve never been meaningful supporters of government cost-containment efforts. He predicts that premium increases expected next year could lead to a new wave of higher deductibles and other forms of cost sharing for the 155 million Americans who rely on employer coverage. Read…

  • KFF/AP Rural Voters Survey

    Poll Finding

    The KFF/AP Rural Voters Survey examines the views and political priorities of voters living in rural areas across the United States ahead of the 2026 midterm elections. The survey gauges rural voters' top election issues, growing struggles with cost of living and health care costs, as well as views on the Trump administration's health care policies.

  • What Could New Anti-Obesity Drugs Mean for Medicare?

    Policy Watch

    In this piece, we discuss Medicare coverage of obesity treatments, the potential cost implications if Medicare covers anti-obesity drugs, and how the Inflation Reduction Act could potentially address these cost concerns.